The end of the year 2009 approaches, and it seems like yesterday when we wrote our first editorial describing the activities of the International Journal of Artificial Organs in the year 2008 (1) . In this timeframe, much work has been done to pursue new strategies to enhance quality and scientific ranking of the "Blue Journal". In this editorial, we will provide a short update on some outcomes of our activity in the last year and a half, and a few thoughts about the new structure of the Blue Journal in 2010.
As anticipated in the December 2008 editorial, a key point in our strategy was to consolidate the legacy of the Blue Journal, in terms of its European character and mission, to broaden it up, and integrate it with the requirements presented by the world situation and advancements in science.
The analysis reported in the press of the new world economy and demography suggests that countries that once were considered emerging economies in the East and Far East have now become established industrial powers. Over the last few years, in these countries major financial investments have been made in these regions (and are still being made) in education and science to promote the development of the country. Since we started serving as Editors of the Blue Journal, efforts have been made to attract more quality submissions and involve in the editorial activities of the Blue Journal more scientists from the Middle East, East and Far East countries. Scientists from China have responded with the greatest enthusiasm, and have contributed a significant number of papers to the Blue Journal in the last year and a half.
Analysis of these papers shows the quality of research in China, and how Chinese research in the field of substitutive medicine in that country spans the spectrum from traditional to very innovative topics.
As is traditional in the Blue Journal, a consistent number of published papers focused on how to exploit the therapeutic use of extracorporeal blood treatment processes and minimize the harm to patients caused by incidents to the vascular access. Tao et al (2) and Yu et al (3) reported on the improvement of monocyte function and the restoration of immune homeostasis during the veno-venous hemofiltration treatment of severe pancreatitis in a porcine pancreatitis model or in patients, respectively. The improvement was more significant in non-septic patients in the early phase of the disease. Mao et al (4) reported on the results of a prospective, pilot study on the effects of coupled plasma filtration and adsorption (CPFA), as compared to high volume hemofiltration (HVHF), on the immune function of patients with multiple organ dysfunction syndrome. They showed that CPFA increases the anti-inflammatory to pro-inflammatory mediators ratio, improves antigen presentation ability, and restores leukocyte responsiveness to a larger extent than HVHF. A silent, but potentially hazardous complication of catheter fracture in a totally implantable venous access port was reported by Wang et al (5) . After a saline flush, the subcutaneous tissue around the port presented a painful, rapid swelling. A chest CT scan showed that the catheter had fractured, and that a fragment had migrated and was embolized into the right hepatic vein. Percutaneous transfemoral retrieval of the catheter fragment under fluoroscopic guidance was successfully performed and avoided more serious com-
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Last but not least, Zhang et al (15) reported on how the advancements of engineering and medical science can be exploited for the development of a novel axial flow ventricular assist device at the Fu Wai Hospital in Beijing.
We are thankful to the Chinese scientists and to all the scientists from Middle East, East and Far East countries who collaboratively contributed the Blue Journal. We will continue to work at making the IJAO instrumental for further promoting the exchange of information and collaboration among scientists to make it possible to offer patients, throughout the world, the best possible assistance. This will confirm and expand the natural "international" attitude of the International Journal of Artificial Organs.
When we began serving as Editors of the Blue Journal, we pledged to broaden the topics of interest to keep our Readers updated on the most advanced or interesting scientific issues in the field of artificial, bioartificial and tissue-engineered organs. One such topic, vascular access, has re-emerged as a linchpin of success of extracorporeal treatments, or in the administration of drugs in chemotherapy. Vascular access has in the last year been given adequate space in the Blue Journal. In their review, Niyyar and Work (16) have nicely discussed how vascular access care has evolved significantly over the last decade since the original Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines were published in 1997 to improve vascular access outcomes in the United States. During the last decade, Interventional Nephrology has become a distinct nephrology subspecialty whose history and scope are reviewed in (16) . In spite of this, vascular access for hemodialysis and peritoneal access, for peritoneal dialysis, are still associated with increased morbidity, mortality, and medical care costs. The unresolved problems that couse these poor outcomes were thoroughly discussed by Gallieni et al in the same issue (17) .
Experimental techniques and theoretical models to evaluate the hydraulic resistance of vascular access have been proposed by Naka et al (18) and Andrew et al (19) , respectively. Detection and care of the silent complications resulting from the fracture of a catheter, or the obstruction of the blood flow in the superior vena cava caused by the indwelling central venous catheter, have been reported and discussed by Wang et al (5) and Pipili et al (20) . However, an important role in the failure of a vascular access is played by the formation of a biofilm in implanted cath-plications. We think that reports like these may help clinicians understand the possible causes and consequences of apparently insignificant or obscure symptoms, allowing them to timely treat the affected patients.
Transplantation of a tissue-compatible organ still remains the gold-standard in the treatment of pathologies that seriously undermine the viability and function of a kidney or a liver. Preventing rejection or monitoring the metabolic function of a transplanted organ may help maintain the homeostasis of transplanted patients. The combination of commercial drugs to improve renal allograft survival (6) and the use of one of them for a specific case, such as hepatitis C-positive, ABO-incompatible renal transplanted patients (7) , was reported by Tsai et al. Hang et al validated in a rat model a novel, simple and reliable method to detect bile in a transplanted liver as a means to monitor its function (8) .
Engineering human tissues and organs in vitro by seeding a suitably large mass of the patient's own cells in a resorbable scaffold in the presence of physiological biochemical and physical cues is considered by many to be very promising for damaged or dead tissue replacement. A significant number of papers was published in the IJAO by Chinese scientists dealing with the engineering of liver, bladder and cartilage tissue, which testifies to the engagement of our colleagues in this challenging field. Isolation and cryopreservation of adult human hepatocytes and in vitro large-scale cultivation of free and microencapsulated immortalized human hepatocytes were discussed by Hang et al (9) and Yu et al (10) , respectively. Zhu et al (11) showed that subcutaneous implantation of encapsulated BHK-21 model cells triggers an increase of free radicals which does not compromise cell viability for the protection offered by the capsule wall. Chen et al (12) reported that the use of bladder acellular matrix grafts may help bladder tissue regeneration by yielding the formation of histologically sound tissue with electrophysiological and pharmacological characteristics similar to natural bladder tissue.
A composite scaffold consisting of polyglycolic acid and hydroxyapatite, seeded with mesenchymal stem cells, was shown to facilitate articular cartilage and subchondral bone regeneration in an animal model of osteochondral defect by Zhou et al (13) . The importance given to the development of new functional biomaterials is confirmed by Shi et al (14) , who reported on the development of implants with bioactive titanium surfaces with bacterial to overcome the limitations of autologous tissue transfer, and allografts and prosthetic replacements in the replacement of long circumferential tracheal defects. They seeded autologous epithelial cells and mesenchymal stem cell (MSCs)-derived chondrocytes onto a decellularized donor tracheal segment, and cultured it in a bioreactor to provide adequate mechanical and biochemical cues. The resulting construct was successfully implanted to replace the left main bronchus of a 31-year-old patient with endstage bronchomalacia: immediately after transplantation, the construct provided the recipient with a functional airway without the need for immunosuppressive therapy.
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In the year 2009, the International Journal of Artificial Organs has seen its scientific rank increase to an Impact Factor of 1.299 thus confirming its emerging role as source of reference in the field of Artificial Organs.
We may anticipate happy that, as of January 1 st 2010, the Blue Journal will not be the same as it so far. Its editorial structure will significantly change: the number of Section Editors and Editorial Board Members will decrease to make it possible for us to have closer contacts and interactions with them; together with the Publisher and the Board of Governors of the european Society for Artificial Organs, we have agreed to introduce a policy limiting the time of participation in the Editorial Board to permit a larger number of scientists to be actively involved in editorial activities of the Blue Journal. We would truly like to see younger investigators and women scientists more involved in order to have an Editorial Board capable of promoting innovation in the Blue Journal and bringing a different perspective. We recognize that innovation and even controversy is a necessary aspect of the dialogue that the Blue Journal can conduct to lead to progress and development in the field of artificial, bioartificial and tissue engineered organs.
The topics each section deals with will be updated and grouped differently. International experts have already kindly agreed to serve as Section Editors and devote considerable time and effort to improving the quality and scientific ranking of the Blue Journal. We thank them heartily for their commitment and for accepting on this challenge together with us. eters. In fact, embedding in the biofilm increases bacterial cell resistance against antibiotics and jeopardizes the pharmacological therapies aiming at eliminating the infection. In consideration of the importance of the problem, the entire September issues of 2008 and 2009 were devoted to implant infections. The role of central venous catheters in catheter-related bacteremia in hemodialysis patients was discussed by Troidle and Finkelstein (21) . Strategies to prevent the infection of vascular catheters by adherence to optimal infection control guidelines, or by means of intra-catheter leukocyte culture to monitor catheter colonization have been reported and discussed by Darouiche (22) and Del Pozo et al (23) . In his exhaustive review, Del Pozo discusses the types of antibiotics and their concentration, the addition of heparin, and the duration of the antimicrobial therapy in an antibiotic lock therapy to retain an infected intraluminal catheter or as a prophylaxis for catheter infection in selected patients, in view of the guidelines issued by the Infectious Diseases Society of America (24) .
Exciting new advancements are also to be expected by the application of tissue-engineering approach and methods to the development in vitro of airways tissue all the way from oral mucosa to the pulmonary tree. One may get an idea of what may soon be available in the clinics in a few articles published in the year 2009 in the Blue Journal. Garzon et al (25) reported that a bioengineered mucosa, made by culturing keratinocytes isolated from human oral mucosa in adhesion on a construct in which fibroblasts isolated from human oral mucosa were immobilized on a scaffold of agarose and fibrin, expressed cytokeratin in a similar way to natural mucosa at an early stage of development. Fritsche et al (26) showed that the basic structure of alveolar tissue may be engineered in vitro by using microfabrication techniques. In their approach, the pulmonary air-blood interface is reproduced by fabricating a dual-chamber polydimethylsiloxane construct, in which the first chamber was designed as a capillary network to mimic the pulmonary microvasculature and the second chamber was designed to permit gas exchange. They reported that immortalized mouse lung epithelium cells cultured on the surface of polystyrene microcarrier beads injected into the second chamber while medium was kept flowing in the first chamber proliferated and remained viable and functional for over a week. In their nice review, Asnaghi et al (27) reported on their approach to developing tissue-engineered tracheal tissue
